A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Phase 1
Completed
- Conditions
- Relapsed/Refractory Mantle Cell LymphomaRelapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory MyelodysplasiaRelapsed/Refractory MyelofibrosisAdenoid Cystic CarcinomaRefractory Chronic Myelomonocytic LeukemiaRelapsed/Refractory Advanced Solid TumorsRelapsed/Refractory Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 232
- Registration Number
- NCT03886831
- Locations
- 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath